C5 deficiency and meningitis in a Swiss family

Clinical Experience with Aurora Kinase Inhibitors: A Review

“…AS703569 (R763), developed by Merck Serono (Darmstadt, Germany) and Rigel Pharmaceuticals (South San Francisco, CA), is an orally available ATP-competitive inhibitor of auroras A, B, and C. The compound also inhibits other cancer-related kinases, including FLT3, making this compound a good candidate for evaluation in patients with hematological malignancies. The drug demonstrated potent inhibition of several tumor cell lines in vitro, and in xenograft studies [75]. Three phase I studies are ongoing, two of which were recently presented at international meetings.…”

Kinase Inhibitors of Marine Origin

“…Tozasertib appeared to be particularly effective in bone marrow mononuclear cells obtained from acute myeloid leukemia (AML) patients with high Aurora A expression . Other Aurora kinase inhibitors in clinical development include PHA-739358 (Nerviano Medical Sciences, Italy), AS703569 (Merck), AT9283 (Astex Therapeutics), SNS-314 (Sunesis Pharma), PF-03814735 (Pfizer), CYC116 (Cyclacel Pharma), and MK5108 (VX-689). Several other Aurora kinase inhibitors are at the preclinical stage.…”

Immunomodulation With Intravenous Immunoglobulin

“…Factor Vlll inhibitors may cause a coagulopathy similar to hemophilia. Inhibitors may be acquired in patients with underlying autoimmune disorders or malignancies, or in hemophiliacs after treatment with factor V111.59 Several reports documented the activity of IVlG in acquired factor Vlll inhibitor^.^^, [60][61][62] Two patients with spontaneously acquired factor VIII:C inhibitors failed to respond to Eleven patients received IVlG (product unspecified) 400 mg/kg for 5 days, cyclophosphamide, and human factor Vlll to induce immune tolerance (elimination of inhibitors and normalization of factor Vlll half-life).64 This triple therapy achieved immune tolerance in nine patients that was sustained for a median of 30 months. One patient failed lVlG but responded to the combination of prednisone, cyclophosphamide, and porcine factor V111.…”